{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:40:08Z","timestamp":1751704808889,"version":"3.41.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"DOI":"10.7759\/cureus.87316","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:15:36Z","timestamp":1751703336000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Metabolic Acidosis Related to Simultaneous Use of Metformin and Dapagliflozin: A Case Report"],"prefix":"10.7759","author":[{"given":"Irene","family":"De la Rosa-Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Carmen","family":"Andreo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo Jos\u00e9","family":"Pardo-Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas TA","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023, 13:15922. 10.1038\/s41598-023-42989-z","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan K","year":"2019","unstructured":"Donnan K, Segar L. SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019, 846:23-9. 10.1016\/j.ejphar.2019.01.002","journal-title":"Eur J Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35497","article-title":"Life-threatening acidosis with metformin and dapagliflozin combination therapy: a case report","volume":"15","author":"Gupta S","year":"2023","unstructured":"Gupta S, Mohta A, Temitope S. Life-threatening acidosis with metformin and dapagliflozin combination therapy: a case report. Cureus. 2023, 15:e35497. 10.7759\/cureus.35497","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14724","article-title":"Metformin-SGLT2, dehydration, and acidosis potential","volume":"65","author":"D'Elia JA","year":"2017","unstructured":"D'Elia JA, Segal AR, Weinrauch LA. Metformin-SGLT2, dehydration, and acidosis potential. J Am Geriatr Soc. 2017, 65:e101-2. 10.1111\/jgs.14724","journal-title":"J Am Geriatr Soc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2025.02.018","article-title":"A case of concurrent metformin-associated lactic acidosis and euglycemic diabetic ketoacidosis","author":"Tomita D","year":"2025","unstructured":"Tomita D, Bamba Y, Kuwabara N, et al.. A case of concurrent metformin-associated lactic acidosis and euglycemic diabetic ketoacidosis. J Emerg Med. 2025, 10.1016\/j.jemermed.2025.02.018","journal-title":"J Emerg Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80989","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitor- and metformin-associated euglycemic diabetic ketoacidosis and lactic acidosis leading to refractory acute kidney injury: successful management with hemodialysis","volume":"17","author":"Yoshida N","year":"2025","unstructured":"Yoshida N, Tanaka T, Suzuki Y, et al.. Sodium-glucose cotransporter 2 (SGLT2) inhibitor- and metformin-associated euglycemic diabetic ketoacidosis and lactic acidosis leading to refractory acute kidney injury: successful management with hemodialysis. Cureus. 2025, 17:e80989. 10.7759\/cureus.80989","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377894-severe-metabolic-acidosis-related-to-simultaneous-use-of-metformin-and-dapagliflozin-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:15:36Z","timestamp":1751703336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377894-severe-metabolic-acidosis-related-to-simultaneous-use-of-metformin-and-dapagliflozin-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.87316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}